HLB bioStep Co.,Ltd. (KOSDAQ:278650)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,491.00
-3.00 (-0.20%)
Last updated: Jun 26, 2025
-36.42%
Market Cap 130.42B
Revenue (ttm) 60.18B
Net Income (ttm) -8.07B
Shares Out 84.47M
EPS (ttm) -95.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 255,636
Average Volume 263,489
Open 1,497.00
Previous Close 1,494.00
Day's Range 1,465.00 - 1,497.00
52-Week Range 1,458.00 - 3,265.00
Beta 0.16
RSI 35.67
Earnings Date Aug 14, 2025

About HLB bioStep

HLB bioStep Co.,Ltd. provides various test services. It offers platform technology services, such as cell-enzyme-based screening, xenograft assay, mitogenic effect test, vaccine antigen, antibody titration, cytokine, MRNA expression, trachea relaxation assay, carrageenan, adjuvant induced paw edema, antipyretic, anti-pain test, isolated blood vessel screening, fibrin plate lysis screening, ferric chloride induced model, food diet induced model, gastric acid secretion, emesis model, MIC test, post antibody effect, enzyme assay, systemic, local i... [Read more]

Industry Commercial Physical and Biological Research
Founded 2012
Employees 150
Stock Exchange KOSDAQ
Ticker Symbol 278650
Full Company Profile

Financial Performance

In 2024, HLB bioStep's revenue was 58.17 billion, an increase of 10.14% compared to the previous year's 52.81 billion. Losses were -8.56 billion, 5120.8% more than in 2023.

Financial Statements

News

There is no news available yet.